

| Study Locations ISABELA (1)+(2) |           |                        |            |
|---------------------------------|-----------|------------------------|------------|
| Region                          | Locations | Region                 | Locations  |
| Australia (1)                   | 4         | Argentina (2)          | 4          |
| Belgium (1)                     |           | Brazil (2)             |            |
| Chile (1)                       | 1         | Canada (2)             |            |
| Czech Republic (1)              | 3         | France (2)             | 4          |
| Denmark (1)                     | 3         | Hungary (2)            | 4          |
| Finland (1)                     |           | Israel (2)             | 6          |
| Germany (1+2)                   | 9         | Italy (2)              | 3          |
| Greece (1)                      | 3         | Korea, Republic of (2) | 6          |
| Peru (1)                        |           | Mexico (2)             |            |
| Spain (1)                       | 8         | Netherlands (2)        | 4          |
| Taiwan (1)                      | 4         | New Zealand (2)        | 3          |
| Turkey (1)                      | 1         | Poland (2)             | 7          |
| United Kingdom (1)              | 3         | South Africa (2)       | 2          |
| United States (1+2)             | 35        | <b>TOTAL</b>           | <b>117</b> |



Last update: July 9, 2019

<https://www.isabelastudies.com/studylocations/>

### Galapagos GLPG1690: ISABELA trials

| ISABELA1       |             |          |         |            |
|----------------|-------------|----------|---------|------------|
| Region         | EEA/non-EEA | patients | centers | recruiting |
| Australia      | non-EEA     | na       | na      | 4          |
| Belgium        | EEA         | ?        | ?       | 1          |
| Chile          | non-EEA     | na       | na      | 1          |
| Czech Republic | EEA         | 80       | 4       | 2          |
| Denmark        | EEA         | 15       | 3       | 3          |
| Finland        | EEA         | ?        | ?       | 0          |
| Germany        | EEA         | 81       | 8       | 3          |
| Greece         | EEA         | 37       | 5       | 3          |
| Peru           | non-EEA     | na       | na      | 0          |
| Spain          | EEA         | 88       | 8       | 8          |
| Taiwan         | non-EEA     | na       | na      | 2          |
| Turkey         | non-EEA     | na       | na      | 0          |
| United Kingdom | EEA         | ?        | ?       | 2          |
| United States  | non-EEA     | na       | na      | 19         |
|                |             |          |         |            |
|                | all         | 750      |         | 48         |
|                | all EEA     | 240      | 43      | 22         |
|                | all non-EEA | 510      |         | 26         |

| ISABELA2           |             |          |          |            |
|--------------------|-------------|----------|----------|------------|
| Region             | EEA/non-EEA | patients | centers  | recruiting |
| Argentina          | non-EEA     | na       | na       | 0          |
| Brazil             | non-EEA     | na       | na       | 0          |
| Canada             | non-EEA     | na       | na       | 3          |
| France             | EEA         | 63       | 4        | 4          |
| Germany            | EEA         | ?        | ?        | 3          |
| Hungary            | EEA         | 29       | multiple | 4          |
| Israel             | non-EEA     | na       | na       | 6          |
| Italy              | EEA         | ?        | ?        | 3          |
| Korea, Republic of | non-EEA     | na       | na       | 5          |
| Mexico             | non-EEA     | na       | na       | 0          |
| Netherlands        | EEA         | 43       | 6        | 5          |
| New Zealand        | non-EEA     | na       | na       | 4          |
| Poland             | EEA         | 51       | 8        | 6          |
| South Africa       | non-EEA     | na       | na       | 1          |
| United States      | non-EEA     | na       | na       | 15         |
|                    |             |          |          |            |
|                    | all         | 750      |          | 59         |
|                    | all EEA     | 185      | 35       | 25         |
|                    | all non-EEA | 565      |          | 34         |

| ISABELA 1+2 |         |            |
|-------------|---------|------------|
| patients    | centers | recruiting |
| 1500        | > 200   | 107        |
| 425         | 78      | 47         |
| 1075        | > 122   | 60         |

Last update: June 18, 2019

EEA = European Economic Area

patients: planned number of subjects, based on info of clinicaltrialsregister.eu (EEA only)

centers: planned number of sites, based on info of clinicaltrialsregister.eu (EEA only)

recruiting centers: currently recruiting, based on info of clinicaltrials.gov

Barclays report: "230 sites globally"